JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Cytek Biosciences Inc

Închisă

SectorSănătate

4.42 -3.49

Rezumat

Modificarea prețului

24h

Curent

Minim

4.35

Maxim

4.55

Indicatori cheie

By Trading Economics

Venit

-39M

-44M

Vânzări

9.8M

62M

Marjă de profit

-70.929

Angajați

702

EBITDA

4M

-263K

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+40.13% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

12M

573M

Deschiderea anterioară

7.91

Închiderea anterioară

4.42

Sentimentul știrilor

By Acuity

50%

50%

177 / 348 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Cytek Biosciences Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 apr. 2026, 23:33 UTC

Acțiuni populare

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 apr. 2026, 23:24 UTC

Câștiguri

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 apr. 2026, 23:15 UTC

Evenimente importante

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 apr. 2026, 22:46 UTC

Câștiguri

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 apr. 2026, 22:37 UTC

Câștiguri

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 apr. 2026, 22:15 UTC

Câștiguri
Evenimente importante

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 apr. 2026, 23:33 UTC

Market Talk
Evenimente importante

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 apr. 2026, 23:31 UTC

Câștiguri

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 apr. 2026, 23:31 UTC

Câștiguri

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 apr. 2026, 23:30 UTC

Câștiguri

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 apr. 2026, 23:30 UTC

Câștiguri

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 apr. 2026, 23:19 UTC

Market Talk
Câștiguri

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 apr. 2026, 23:09 UTC

Câștiguri

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 apr. 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 apr. 2026, 23:01 UTC

Evenimente importante

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 apr. 2026, 23:01 UTC

Evenimente importante

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 apr. 2026, 23:01 UTC

Evenimente importante

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 apr. 2026, 23:01 UTC

Evenimente importante

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 apr. 2026, 23:01 UTC

Evenimente importante

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 apr. 2026, 22:51 UTC

Câștiguri

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 apr. 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 apr. 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 apr. 2026, 22:40 UTC

Market Talk
Evenimente importante

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 apr. 2026, 22:32 UTC

Câștiguri

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 apr. 2026, 22:25 UTC

Achiziții, Fuziuni, Preluări

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 apr. 2026, 22:22 UTC

Câștiguri

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 apr. 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 apr. 2026, 22:14 UTC

Câștiguri

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 apr. 2026, 22:14 UTC

Câștiguri

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 apr. 2026, 22:07 UTC

Market Talk
Evenimente importante

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparație

Modificare preț

Cytek Biosciences Inc Așteptări

Obiectiv de preț

By TipRanks

40.13% sus

Prognoză pe 12 luni

Medie 6.25 USD  40.13%

Maxim 7.5 USD

Minim 5 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCytek Biosciences Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

3.7 / 3.8Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

177 / 348 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat